EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSOTSG00005034765
Gene Symbol: PSMD8
1 Cross references
211 Possible Orthologues:

Proteasome Subunit Alpha Type-3

Ensembl ID : ENSOTSG00005000793
Gene Symbol: LOC112256851
3 Cross references
232 Possible Orthologues:

Proteasome Subunit Alpha Type-3-Like

Ensembl ID : ENSOTSG00005014241
Gene Symbol: LOC112233416
3 Cross references
232 Possible Orthologues:

Proteasome Subunit Alpha Type-3-Like

Ensembl ID : ENSOTSG00005034746
Gene Symbol: LOC112233416
3 Cross references
232 Possible Orthologues:

Proteasome Subunit Alpha Type-7-Like

Ensembl ID : ENSOTSG00005011680
Gene Symbol: LOC112251291
3 Cross references
130 Possible Orthologues:

Proteasome Subunit Alpha Type-7-Like

Ensembl ID : ENSOTSG00005047283
Gene Symbol: LOC112246656
3 Cross references
130 Possible Orthologues:

Proteasome Subunit Alpha Type-7-Like

Ensembl ID : ENSOTSG00005032475
Gene Symbol: LOC112246656
3 Cross references
130 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSOTSG00005047911
Gene Symbol: PSMB11
1 Cross references
164 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSOTSG00005040906
Gene Symbol: PSMB11
1 Cross references
163 Possible Orthologues:

Proteasome Subunit Beta Type-3

Ensembl ID : ENSOTSG00005035603
Gene Symbol: LOC112245683
3 Cross references
252 Possible Orthologues:

Proteasome Subunit Beta Type-3

Ensembl ID : ENSOTSG00005039706
Gene Symbol: LOC112245683
3 Cross references
252 Possible Orthologues:

Proteasome Subunit Beta Type-3-Like

Ensembl ID : ENSOTSG00005043741
Gene Symbol: LOC112245608
3 Cross references
253 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).